Clinical Trial Update: Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating atezolizumab with carboplatin and etoposide in extensive-stage small cell lung cancer patients with ECOG performance status 2 has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: SCLC, Extensive Stage | Phase 2 | Status: COMPLETED